Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124083213 | 12408321 | 3 | F | 20160519 | 20160914 | 20160526 | 20160920 | PER | US-PFIZER INC-2016270222 | PFIZER | 60.00 | YR | F | Y | 59.00000 | KG | 20160920 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124083213 | 12408321 | 1 | PS | REVATIO | SILDENAFIL CITRATE | 1 | Oral | 20 MG, 3X/DAY | 21845 | 20 | MG | FILM-COATED TABLET | TID | ||||||
| 124083213 | 12408321 | 2 | SS | REVATIO | SILDENAFIL CITRATE | 1 | 20 MG, 3X/DAY | A563501 | 21845 | 20 | MG | FILM-COATED TABLET | TID | ||||||
| 124083213 | 12408321 | 3 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 40 MG 1/2 DAILY | 0 | 20 | MG | |||||||||
| 124083213 | 12408321 | 4 | C | ELIQUIS | APIXABAN | 1 | 5 MG, 2X/DAY | 0 | 5 | MG | BID | ||||||||
| 124083213 | 12408321 | 5 | C | ATORVASTATIN | ATORVASTATIN | 1 | 40 MG, 1X/DAY | 0 | 40 | MG | QD | ||||||||
| 124083213 | 12408321 | 6 | C | MIRTAZAPINE. | MIRTAZAPINE | 1 | 15 MG, 1X/DAY (15 MGS 1 @ BED TIME) | 0 | 15 | MG | QD | ||||||||
| 124083213 | 12408321 | 7 | C | Hydroxyz Pam | HYDROXYZINE PAMOATE | 1 | 25 MG, 2X/DAY | 0 | 25 | MG | BID | ||||||||
| 124083213 | 12408321 | 8 | C | METOPROLOL. | METOPROLOL | 1 | 50 MG, 2X/DAY | 0 | 50 | MG | BID | ||||||||
| 124083213 | 12408321 | 9 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 25 MG, 1X/DAY | 0 | 25 | MG | QD | ||||||||
| 124083213 | 12408321 | 10 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | 18 MG, 1X/DAY | 0 | 18 | MG | QD | ||||||||
| 124083213 | 12408321 | 11 | C | ADVAIR DISKUS | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | 250/50, 2X/DAY | 0 | BID | ||||||||||
| 124083213 | 12408321 | 12 | C | PROAIR HFA | ALBUTEROL SULFATE | 1 | 90 UG, AS NEEDED (EVERY 4 TO 6 HOUS AS NEEDED) | 0 | 90 | UG | |||||||||
| 124083213 | 12408321 | 13 | C | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | 5 MG, 1X/DAY (1 DAILY (NIGHT TIME)) | 0 | 5 | MG | QD | ||||||||
| 124083213 | 12408321 | 14 | C | VITAMIN D2 | ERGOCALCIFEROL | 1 | 1 DF, WEEKLY (50,000 UNITS 1 TAB WEEKLY ) | 0 | 1 | DF | TABLET | /wk |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124083213 | 12408321 | 1 | Pulmonary hypertension |
| 124083213 | 12408321 | 2 | Lung disorder |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124083213 | 12408321 | Condition aggravated | |
| 124083213 | 12408321 | Dyspnoea | |
| 124083213 | 12408321 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124083213 | 12408321 | 2 | 20141108 | 0 | ||
| 124083213 | 12408321 | 4 | 2015 | 20160608 | 0 | |
| 124083213 | 12408321 | 5 | 2014 | 0 | ||
| 124083213 | 12408321 | 6 | 2013 | 0 | ||
| 124083213 | 12408321 | 7 | 2013 | 0 | ||
| 124083213 | 12408321 | 8 | 2015 | 0 | ||
| 124083213 | 12408321 | 9 | 2016 | 0 | ||
| 124083213 | 12408321 | 10 | 2011 | 0 | ||
| 124083213 | 12408321 | 11 | 2011 | 0 | ||
| 124083213 | 12408321 | 12 | 2011 | 0 | ||
| 124083213 | 12408321 | 13 | 20140531 | 0 | ||
| 124083213 | 12408321 | 14 | 20140505 | 0 |